Skip to content
2000
Volume 26, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

With respect to the total cure failure of current drugs used in the treatment of neurodegenerative diseases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuroprotection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612826666200131103524
2020-02-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612826666200131103524
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test